Lyons Patrick G, Snyder Ashley, Sokol Sarah, Edelson Dana P, Mokhlesi Babak, Churpek Matthew M
Washington University School of Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine, St. Louis, Missouri.
The University of Chicago Medicine, Department of Medicine, Section of Hospital Medicine, Chicago, Illinois.
J Hosp Med. 2017 Jun;12(6):428-434. doi: 10.12788/jhm.2749.
Opioids and benzodiazepines are frequently used in hospitals, but little is known about outcomes among ward patients receiving these medications.
To determine the association between opioid and benzodiazepine administration and clinical deterioration.
Observational cohort study.
500-bed academic urban tertiary-care hospital.
All adults hospitalized on the wards from November 2008 to January 2016 were included. Patients who were "comfort care" status, had tracheostomies, sickle-cell disease, and patients at risk for alcohol withdrawal or seizures were excluded.
The primary outcome was the composite of intensive care unit transfer or ward cardiac arrest. Discrete-time survival analysis was used to calculate the odds of this outcome during exposed time periods compared to unexposed time periods with respect to the medications of interest, with adjustment for patient demographics, comorbidities, severity of illness, and pain score.
In total, 120,518 admissions from 67,097 patients were included, with 67% of admissions involving opioids, and 21% involving benzodiazepines. After adjustment, each equivalent of 15 mg oral morphine was associated with a 1.9% increase in the odds of the primary outcome within 6 hours (odds ratio [OR], 1.019; 95% confidence interval [CI], 1.013-1.026; P < 0.001), and each 1 mg oral lorazepam equivalent was associated with a 29% increase in the odds of the composite outcome within 6 hours (OR, 1.29; CI, 1.16- 1.45; P < 0.001).
Among ward patients, opioids were associated with increased risk for clinical deterioration in the 6 hours after administration. Benzodiazepines were associated with even higher risk. These results have implications for ward-monitoring strategies. Journal of Hospital Medicine 2017;12:428-434.
阿片类药物和苯二氮䓬类药物在医院中经常使用,但对于接受这些药物治疗的病房患者的治疗结果了解甚少。
确定阿片类药物和苯二氮䓬类药物的使用与临床病情恶化之间的关联。
观察性队列研究。
一家拥有500张床位的城市学术型三级护理医院。
纳入2008年11月至2016年1月期间在病房住院的所有成年人。处于“舒适护理”状态、行气管切开术、患有镰状细胞病以及有酒精戒断或癫痫发作风险的患者被排除。
主要结局是重症监护病房转诊或病房心脏骤停的复合结局。采用离散时间生存分析来计算在暴露时间段内与未暴露时间段相比,就感兴趣的药物而言该结局的几率,并对患者人口统计学特征、合并症、疾病严重程度和疼痛评分进行调整。
总共纳入了来自67097名患者的120518次住院病例,其中67%的住院病例涉及阿片类药物,21%涉及苯二氮䓬类药物。调整后,每15毫克口服吗啡等效剂量与6小时内主要结局几率增加1.9%相关(比值比[OR],1.019;95%置信区间[CI],1.013 - 1.026;P < 0.001),每1毫克口服劳拉西泮等效剂量与6小时内复合结局几率增加29%相关(OR,1.29;CI,1.16 - 1.45;P < 0.001)。
在病房患者中,阿片类药物与给药后6小时内临床病情恶化风险增加相关。苯二氮䓬类药物与更高的风险相关。这些结果对病房监测策略具有启示意义。《医院医学杂志》2017年;12:428 - 434。